These results follow from an analysis of asymptomatic, positive COVID-19 cases in cancer patients during the outbreak of the alpha variant between December 2020 and February 2021.
The new study, led by Professor Mieke Van Hemelrijck of the School of Cancer & Pharmaceutical Sciences, analyzed data from cancer patients who participated in Guy’s and St Thomas’ NHS Foundation Trust.
A major driving force in the UK’s second wave of COVID-19 was the development and proliferation of the alpha variant, which was associated with a higher transfer rate.
A common side effect of cancer and cancer treatments is the death of immune cells, which reduces the patient’s ability to fight infections such as COVID-19. As a precautionary measure, treatments and follow-up treatment for cancer were interrupted or paused during the second wave.
To assess the risk of infection in cancer patients, the authors analyzed COVID-19 positivity rates during the second (alpha variant-driven) wave of COVID-19.
Data were collected from 1,346 patients who tested positive with asymptomatic COVID-19 cases and a logistic regression was performed. This statistical model was used to analyze the factors associated with COVID-19.
The results, published in The oncology of the future, showed that an increased number of tests taken by asymptomatic humans and living less than 20 km (12.4 miles) from the epicenter of the alpha variant (the area of south-east England associated with its first outbreak) were associated with higher positive rates.
The latter is a particularly important factor, as Guy’s Cancer Center serves many patients living in Kent and London, where the alpha variant first spread.
However, attending Guy’s and St Thomas’ NHS Foundation Trust was not associated with an increased chance of patients testing positive.
These results suggest that PPE and guidelines for social distancing have so far effectively reduced the risk of cancer patients receiving COVID-19. As a result, the authors continue to support cancer treatment and patient care.
These findings will be important for efforts to improve cancer treatment and treatment outcomes as we begin to assess and address the impact of COVID-19-related delays and disorders.
British study suggests that COVID-19 became much more lethal by the end of 2020
Kathryn Tremble et al., The impact of hospitalization on COVID-19 infection in cancer patients: an evaluation of data from Guy’s Cancer, The oncology of the future (2022). DOI: 10.2217 / fon-2021-1329
Provided by King’s College London
Citation: Hospitalization not associated with increased risk of COVID transfer (2022, 17 January) retrieved 17 January 2022 from https://medicalxpress.com/news/2022-01-hospital-covid-transmission.html
This document is subject to copyright. Apart from any reasonable trade for the purpose of private investigation or research, no part may be reproduced without written permission. The content is provided for informational purposes only.